Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEN1611 plus cetuximab in PIK3CA-mutated metastatic colorectal cancer
NL-OMON54485Phase 2Completed
- Sponsor
- Menarini Group
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of izorlisib and cetuximab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Menarini Group. Started Jul 2020; status: completed.
02
Drugs
izorlisibcetuximab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON54485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54485.